Inclusion complex of novel curcumin analogue CDF and ?-cyclodextrin (1:2) and its enhanced in vivo anticancer activity against pancreatic cancer.

ABSTRACT: Several formulations have been proposed to improve the systemic delivery of novel cancer therapeutic compounds, including cyclodextrin derivatives. We aimed to synthesize and characterize of CDF-?-cyclodextrin inclusion complex (1:2) (CDFCD).The compound was characterized by Fourier transform infrared, differential scanning calorimetry, powder X-ray diffraction studies, H1 & C13 NMR studies and scanning electron microscopic analysis. Its activity was tested against multiple cancer cell lines, and in vivo bioavailability was checked.CDF-?-cyclodextrin was found to lower IC(50) value by half when tested against multiple cancer cell lines. It preferentially accumulated in the pancreas, where levels of CDF-?-cyclodextrin in mice were 10 times higher than in serum, following intravenous administration of an aqueous CDF-?-cyclodextrin preparation.Novel curcumin analog CDF preferentially accumulates in the pancreas, leading to its potent anticancer activity against pancreatic cancer cells. Synthesis of such CDF-?-cyclodextrin self-assembly is an effective strategy to enhance its bioavailability and tissue distribution, warranting further evaluation for CDF delivery in clinical settings for treatment of human malignancies.

SUBMITTER: Dandawate PR 

PROVIDER: S-EPMC3868989 | biostudies-literature | 2012 Jul

REPOSITORIES: biostudies-literature